These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37165090)

  • 1. PREP inhibition reduces tau pathology in mouse models.
    Villanueva MT
    Nat Rev Drug Discov; 2023 Jun; 22(6):446. PubMed ID: 37165090
    [No Abstract]   [Full Text] [Related]  

  • 2. Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease.
    Hernández F; Lim F; Lucas JJ; Pérez-Martín C; Moreno F; Avila J
    Mini Rev Med Chem; 2002 Feb; 2(1):51-8. PubMed ID: 12369957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
    Wilcock DM; Gharkholonarehe N; Van Nostrand WE; Davis J; Vitek MP; Colton CA
    J Neurosci; 2009 Jun; 29(25):7957-65. PubMed ID: 19553436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.
    van Eersel J; Ke YD; Liu X; Delerue F; Kril JJ; Götz J; Ittner LM
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13888-93. PubMed ID: 20643941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease.
    Sun XY; Li LJ; Dong QX; Zhu J; Huang YR; Hou SJ; Yu XL; Liu RT
    J Neuroinflammation; 2021 Jun; 18(1):131. PubMed ID: 34116706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau and Alzheimer's disease: the long road to anti-tangle therapeutics.
    Fillit HM; Refolo LM
    J Mol Neurosci; 2002 Dec; 19(3):249-50. PubMed ID: 12540049
    [No Abstract]   [Full Text] [Related]  

  • 9. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage.
    Shibuya Y; Niu Z; Bryleva EY; Harris BT; Murphy SR; Kheirollah A; Bowen ZD; Chang CCY; Chang TY
    Neurobiol Aging; 2015 Jul; 36(7):2248-2259. PubMed ID: 25930235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.
    Robert A; Schöll M; Vogels T
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain.
    Morawe MP; Liao F; Amberg W; van Bergeijk J; Chang R; Gulino M; Hamilton C; Hoft C; Lumpkin C; Mastis B; McGlame E; Nuber J; Plaas C; Ravikumar B; Roy K; Schanzenbächer M; Tierno J; Lakics V; Dellovade T; Townsend M
    Eur J Pharmacol; 2022 Nov; 934():175301. PubMed ID: 36191631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau.
    Brendel M; Deussing M; Blume T; Kaiser L; Probst F; Overhoff F; Peters F; von Ungern-Sternberg B; Ryazanov S; Leonov A; Griesinger C; Zwergal A; Levin J; Bartenstein P; Yakushev I; Cumming P; Boening G; Ziegler S; Herms J; Giese A; Rominger A
    Alzheimers Res Ther; 2019 Aug; 11(1):67. PubMed ID: 31370885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.
    Ayalon G; Lee SH; Adolfsson O; Foo-Atkins C; Atwal JK; Blendstrup M; Booler H; Bravo J; Brendza R; Brunstein F; Chan R; Chandra P; Couch JA; Datwani A; Demeule B; DiCara D; Erickson R; Ernst JA; Foreman O; He D; Hötzel I; Keeley M; Kwok MCM; Lafrance-Vanasse J; Lin H; Lu Y; Luk W; Manser P; Muhs A; Ngu H; Pfeifer A; Pihlgren M; Rao GK; Scearce-Levie K; Schauer SP; Smith WB; Solanoy H; Teng E; Wildsmith KR; Bumbaca Yadav D; Ying Y; Fuji RN; Kerchner GA
    Sci Transl Med; 2021 May; 13(593):. PubMed ID: 33980574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glycogen synthase kinase-3 by BTA-EG
    Croft CL; Kurbatskaya K; Hanger DP; Noble W
    Sci Rep; 2017 Aug; 7(1):7434. PubMed ID: 28785087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased cerebral vascular reactivity in the tau expressing rTg4510 mouse: evidence against the role of tau pathology to impair vascular health in Alzheimer's disease.
    Wells JA; Holmes HE; O'Callaghan JM; Colgan N; Ismail O; Fisher EM; Siow B; Murray TK; Schwarz AJ; O'Neill MJ; Collins EC; Lythgoe MF
    J Cereb Blood Flow Metab; 2015 Mar; 35(3):359-62. PubMed ID: 25515210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.
    Soeda Y; Saito M; Maeda S; Ishida K; Nakamura A; Kojima S; Takashima A
    J Alzheimers Dis; 2019; 68(4):1677-1686. PubMed ID: 30909223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Lauretti E; Craige CP; Praticò D
    J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease.
    Kampers T; Pangalos M; Geerts H; Wiech H; Mandelkow E
    FEBS Lett; 1999 May; 451(1):39-44. PubMed ID: 10356980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease.
    Zhang G; Wu J; Huang C; Cheng J; Su Z; Zhu Z; Yang X; Guo B; Wu L; Zhang Z; Zhang G; Chen H; Sun Y; Wang Y
    J Mol Neurosci; 2021 Jul; 71(7):1456-1466. PubMed ID: 33403592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.